Vertex Pharmaceuticals Buy Hold or Sell Recommendation

VRTX -- USA Stock  

USD 176.14  1.98  1.11%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Vertex Pharmaceuticals Incorpor is 'Strong Hold'. Macroaxis provides Vertex Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VRTX positions. The advice algorithm takes into account all of Vertex Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from VRTX buy-and-hold prospective. Also please take a look at Vertex Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Vertex PharmaceuticalsBuy Vertex Pharmaceuticals
Strong Hold

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon Vertex Pharmaceuticals Incorpor has a risk adjusted performance of (0.003225), jensen alpha of (0.038265), total risk alpha of (0.06), sortino ratio of 0.0 and treynor ratio of (0.037864)
Macroaxis provides recommendation on Vertex Pharmaceuticals to complement and cross-verify current analyst consensus on Vertex Pharmaceuticals Incorpor. Our buy or sell recommendation engine determines the firm potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Vertex Pharmaceuticals is not overpriced, please validate all Vertex Pharmaceuticals fundamentals including its Total Debt, Earnings Per Share and the relationship between Net Income and Book Value Per Share . Given that Vertex Pharmaceuticals has Number of Shares Shorted of 4.23M, we advise you double-check Vertex Pharmaceuticals Incorpor market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Vertex Pharmaceuticals Trading Alerts and Improvement Suggestions

Vertex Pharmaceuticals generates negative expected return over the last 30 days
Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from MacroaxisInsider: Exercise or conversion by Joshua Boger of 11000 shares of Vertex Pharmaceuticals subject to Rule 16b-3

Vertex Pharmaceuticals current analysts recommendations

Target Median Price213.00
Target Mean Price215.84
Recommendation Mean2.00
Target High Price254.00
Number Of Analyst Opinions19
Target Low Price183.00

Vertex Pharmaceuticals Returns Distribution Density

Mean Return0.02Value At Risk2.22
Potential Upside2.26Standard Deviation1.75
 Return Density 
      Distribution 

Vertex Pharmaceuticals Greeks

α
Alpha over DOW
=0.04
β
Beta against DOW=0.68
σ
Overall volatility
=1.76
Ir
Information ratio =0.03

Vertex Pharmaceuticals Volatility Alert

Vertex Pharmaceuticals Incorpor exhibits very low volatility with skewness of 1.29 and kurtosis of 4.54. However, we advise investors to further study Vertex Pharmaceuticals Incorpor technical indicators to make sure all market info is available and is reliable.
    
 Better Than Average     
    
 Worse Than Average Compare Vertex Pharmaceuticals to competition

Vertex Pharmaceuticals Fundamental Vs Peers

FundamentalsVertex PharmaceuticalsPeer Average
Return On Equity56.25% (0.31)%
Return On Asset9.99% (0.14)%
Profit Margin64.13% (1.27)%
Operating Margin29.00% (5.51)%
Current Valuation41.67B16.62B
Shares Outstanding257.04M571.82M
Shares Owned by Insiders0.26% 10.09%
Shares Owned by Institutions96.96% 39.21%
Number of Shares Shorted4.23M4.71M
Price to Earning20.84X28.72X
Price to Book8.99X9.51X
Price to Sales13.21X11.42X
Revenue3.45B9.43B
Gross Profit1.22B27.38B
EBITDA1000M3.9B
Net Income2.21B570.98M
Cash and Equivalents3.95B2.7B
Cash per Share15.37X5.01X
Total Debt656.95M5.32B
Debt to Equity12.90% 48.70%
Current Ratio3.74X2.16X
Book Value Per Share19.75X1.93K
Cash Flow from Operations1.1B971.22M
Short Ratio3.11X4.00X
Earnings Per Share8.52X3.12X
Price to Earnings To Growth0.79X4.89X
Number of Employees2.5K18.84K
Beta1.05-0.15
Market Capitalization45.64B19.03B
Total Asset2.5B29.47B
Retained Earnings(4.71B)9.33B
Working Capital900.8M1.48B
Current Asset1.41B9.34B
   Vertex Pharmaceuticals exotic insider transaction detected [view details]
Search macroaxis.com